weak up OCAT
You know what is the best Interest !!!! He not put the order of K100 on the offer , he selling in small piceses to get the best Price for me!!!
My Broker try in the best interest today --If no buyers in the market he can wait for Friday or Monday
you will not see a spik in volume today if no buy interest in the market !!!
I don´t like the PR politic of the Management is very bad over the last 10 months !!! I´m going with a loses of near $ 500.000 over 3 years!!! If the stockprice coming below .80 Cents than I´m willing to buy back if not goodbye !!! I made better profits with other stocks!!!
100.000 for sell in the best interest !!!
Holding K150 selling today K50 Shares down to K100 sorry !!
no News this year , no News next year ask the Company CEO Garr !!??
selling every day some Shares Holding still K195
that´s live !!!
Program Indication Development Development Plan
NSI - 189 Major Depressive Phase II The Phase II
Disorder preparation trial is
underway. expected to
NSI-189 Cognitive Deficit Phase Ib The Phase Ib
in Schizophrenia preparation. trial is
NSI - 566 Amyotrophic Completion of Preparation for
Lateral Sclerosis Phase II a controlled
(ALS) clinical trial Phase II trial
primarily expected to
evaluating commence in
NSI - 566 Chronic Spinal Ongoing Phase I The Phase I
Cord Injury clinical trials. trial is
NSI - 566 Motor deficits Completion of The Phase II
due to ischemic Phase I clinical trial is
stroke trial evaluating expected to
safety. commence in
Neurogenic Small Molecule Program
•NSI-189 Phase II in Major Depressive Disease (MDD): Neuralstem is developing regulatory and clinical plans for a multicenter, Phase II clinical trial of NSI-189 for the treatment of MDD. Maurizio Fava, M.D., Slater Family Professor of Psychiatry at Harvard Medical School, Massachusetts General Hospital will be the principal investigator. The study is anticipated to enroll approximately 200 patients and expected to begin in the second half of 2015.
•NSI-189 for the treatment of cognitive deficit in schizophrenia: The Company plans to begin a Phase Ib clinical trial for the treatment of cognitive deficit in schizophrenia.
Cell Therapy Program
•NSI-566 spinal cord-derived stem cell therapy, under development for the treatment of ALS: In March, the company announced topline data, concluding that the Phase II ALS clinical trial met the primary safety endpoints and established what we believe to be the maximum-safe-tolerated dose of 16 million cells administered via 40 injections. The Company's collaborators are currently completing a final report on the study. The Company expects to initiate a larger controlled clinical study this year.
•NSI-566 spinal cord-derived cell therapy under development for the treatment of chronic spinal cord injury (cSCI): The four-patient, stem cell transplantation Phase I safety study dosed the last patient in July. Each patient is evaluated over a 6-month post-operative observation period. The trial is being conducted at the UCSD School of Medicine, supported and funded by the UCSD Sanford Stem Cell Clinical Center.
•NSI-566 spinal cord derived stem cell therapy under development for the treatment of motor deficits in stroke: Neuralstem continues to proceed in its collaborative Phase I/II ischemic stroke trial with BaYi Brain Hospital in Beijing. The Phase II portion of the study is expected to commence in 2015. The trial is sponsored by Neuralstem's wholly owned subsidiary, Suzhou Neuralstem Biopharmaceu